modelLurbinectedin

Diagram of Lurbinectedin

Extends from Pharmacolibrary.Drugs.ATC.L.L01XX69.

Information

name:Lurbinectedin
ATC code:L01XX69
route:intravenous
compartments:3
dosage:3.2mg
volume of distribution:504L
clearance:12.1L/h
other parameters in model implementation

Lurbinectedin is an alkylating antineoplastic agent belonging to the tetrahydroisoquinoline family, structurally related to trabectedin. It binds to the minor groove of DNA and inhibits oncogenic transcription, inducing apoptosis in cancer cells. Lurbinectedin is approved for the treatment of metastatic small cell lung cancer (SCLC) in patients who have progressed after prior platinum-based chemotherapy.

Pharmacokinetics

Population pharmacokinetics in adult cancer patients after intravenous infusion, no specific stratification by age or sex.

References

  1. Fernandez-Teruel, C, et al., & Fudio, S (2019). Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer. Clinical pharmacokinetics 58(3) 363–374. DOI:10.1007/s40262-018-0701-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30090974

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.VolumeVdp2 (from PK_3C)Vdp2PerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdp2PerKg (from PK_3C)0.9Volume of distribution peripheral 2 (l/kg)
Pharmacolibrary.Types.VolumeFlowRatek13 (from PK_3C)1intercompartmental 1-3 clearance (l/min)
Pharmacolibrary.Types.VolumeFlowRatek31 (from PK_3C)1intercompartmental 3-1 clearance (l/min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)
Interfaces.ConcentrationPort_bperihperal2Cport (from PK_3C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral2 (from PK_3C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral1 (from PK_3C)
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer1 (from PK_3C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)